Our ******* ysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.
Revenue growth was primarily driven by a 48% increase in ZELSUVMI prescription units, reflecting strong market adoption of the first and only FDA-approved at-home treatment for Molluscum Contagiosum (MC).
Management attributes the 81.3% unit increase within a major PBM to a strategic contract executed late last year, which significantly reduced patient friction and accelerated prescriber acquisition.
The company achieved top-line growth while simultaneously improving operational efficiency, reducing wholesale inventory days on hand by approximately three days during the quarter.
Strategic positioning is bolstered by new expert consensus guidelines published in the Journal of Drugs in Dermatology, which recognize ZELSUVMI as the sole at-home clinical option for pediatric MC.
#strategic #increase #tell
Revenue growth was primarily driven by a 48% increase in ZELSUVMI prescription units, reflecting strong market adoption of the first and only FDA-approved at-home treatment for Molluscum Contagiosum (MC).
Management attributes the 81.3% unit increase within a major PBM to a strategic contract executed late last year, which significantly reduced patient friction and accelerated prescriber acquisition.
The company achieved top-line growth while simultaneously improving operational efficiency, reducing wholesale inventory days on hand by approximately three days during the quarter.
Strategic positioning is bolstered by new expert consensus guidelines published in the Journal of Drugs in Dermatology, which recognize ZELSUVMI as the sole at-home clinical option for pediatric MC.
#strategic #increase #tell
3 months ago
